Skip to main content

Table 1 Clinical characteristics at start of TNFi treatment and changes of outcome measures at follow-up visit (2–8 months) among RA patients overall, and stratified by ACPA status

From: A genetic risk score composed of rheumatoid arthritis risk alleles, HLA-DRB1 haplotypes, and response to TNFi therapy – results from a Swedish cohort study

Characteristic Overall RA ACPA-positive RA ACPA-negative RA
Number of observations 867 653 165
Age, mean 51.2 51.3 51.5
Female (%) 74.1 72.1 79.2
Baseline values, mean
 DAS28 5.0 5.0 5.0
 CRP 21.0 21.9 19.1
 ESR 27.9 29 24.2
 SJC 7.8 7.8 8.1
 TJC 7.8 7.5 8.9
 VAS global health 54.1 53.8 54.5
 VAS pain 53.5 53.4 53.5
 HAQ 1.0 1.0 1.0
Changes from baseline to follow-up visit, mean
 ΔDAS28 –1.5 –1.5 –1.6
 ΔCRP –10.2 –10.4 –9.3
 ΔESR –9.2 –9.5 –8.2
 ΔSJC –4.9 –4.8 –5.3
 ΔTJC –4.3 –4.1 –4.9
 ΔVAS global health –21.1 –21.7 –19.2
 ΔVAS pain –21.6 –22.3 –19.7
 ΔHAQ –0.3 –0.3 –0.3
EULAR response (%)
 No 25.2 25.6 23.6
 Moderate 31.4 30.6 33.1
 Good 43.4 43.8 43.3
  1. ACPA anti-citrullinated protein/peptide antibodies, DAS28 disease activity score 28, CRP C-reactive protein, ESR erythrocyte sedimentation rate, RA rheumatoid arthritis, SJC swollen joint count, TJC tender joint count, TNFi tumor necrosis factor inhibitor, VAS visual analog scale, HAQ Health Assessment Questionnaire, EULAR European League Against Rheumatism